Turn Therapeutics Advances Phase 2 Atopic Dermatitis Trial with First-in-Class IL-36/IL-31 Inhibitor GX-03
核心洞察
Turn Therapeutics' Phase 2 randomized controlled trial of GX-03, a first-in-class IL-36 (搜索)/IL-31 (搜索) pathway inhibitor for moderate-severe atopic dermatitis (搜索), remains on track with both interim analysis and topline data expected in the first half of 2026.
The company has expanded its vaccine pipeline to include an intranasal influenza (搜索) candidate that leverages proprietary delivery technology to potentially stimulate systemic immunity without adjuvants or harmful additives.
Turn Therapeutics strengthened its board with the appointment of Martin Dewhurst, a 30+ year McKinsey veteran, and expects revenue generation in 2026 through its strategic partnership with Medline (搜索) in the advanced wound care market.
Turn Therapeutics is advancing its lead clinical program with GX-03, a first-in-class IL-36 (搜索)/IL-31 (搜索) pathway inhibitor currently in Phase 2 development for moderate-severe atopic dermatitis (搜索). The company announced that enrollment in the randomized controlled trial continues as expected, supporting trial timelines and statistical objectives, with both interim analysis and topline data anticipated in the first half of 2026.
"As we enter 2026, Turn Therapeutics is well positioned with a strengthened balance sheet, advancing clinical programs, a commercial partnership approaching launch, and a broadened pipeline," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. "We believe 2026 is a pivotal year for the Company as we approach meaningful clinical readouts and prepare for commercial execution."
Novel Mechanism Targets Inflammatory Pathways
GX-03 represents a novel therapeutic approach as the first-in-class inhibitor targeting both IL-36 (搜索) and IL-31 (搜索) pathways, which are key inflammatory mediators in atopic dermatitis (搜索). The compound is currently being studied in humans for moderate-severe atopic dermatitis, addressing a significant unmet medical need in dermatologic care.
Pipeline Expansion into Vaccine Development
Turn Therapeutics has expanded its vaccine pipeline to include an influenza (搜索) vaccine candidate that leverages the company's proprietary delivery technology. The intranasal influenza vaccine is designed to be thermostable and capable of rapid deployment during pandemics. The company intends to target intranasal epithelial receptors with the viscous, oil-based candidate to stimulate systemic immunity at a primary site of exposure without adjuvants and potentially harmful additives.
In-vivo and in-vitro studies for the influenza (搜索) vaccine candidate are expected to commence in the first quarter of 2026, representing an expansion of Turn Therapeutics' addressable market and growth opportunities.
Strategic Leadership and Commercial Partnerships
The company has appointed Martin Dewhurst to its Board of Directors, bringing more than 30 years of experience in life sciences, mergers and acquisitions, and corporate strategy from his tenure at McKinsey & Company (搜索). His background in strategic planning and operational leadership is expected to provide guidance as the company advances its clinical development programs and commercial initiatives.
Turn Therapeutics' strategic partnership with Medline (搜索) is expected to generate near-term revenue in 2026 and expand the company's market presence in wound care through its PermaFusion® platform for advanced wound care applications.
Financial Position and 2026 Outlook
The company has strengthened its balance sheet through utilization of its existing share purchase agreement during the quarter. Combined with existing cash reserves, these proceeds extend Turn Therapeutics' operational runway into late 2026, supporting continued execution of clinical and strategic objectives.
Turn Therapeutics has also engaged Damouni Group (搜索) to advance corporate strategy, capital markets positioning, and long-term value creation initiatives, along with a corporate communications refresh of its website and investor materials to enhance clarity and consistency across stakeholder communications.